455 related articles for article (PubMed ID: 14727929)
1. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
Farnier M
Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
[TBL] [Abstract][Full Text] [Related]
4. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment of combined hyperlipidemia.
Wierzbicki AS; Mikhailidis DP; Wray R
Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015
[TBL] [Abstract][Full Text] [Related]
6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
7. Optimal therapy of low levels of high density lipoprotein-cholesterol.
Kashyap ML; Tavintharan S; Kamanna VS
Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Iliadis EA; Rosenson RS
Clin Cardiol; 1999 Jan; 22(1):25-8. PubMed ID: 9929751
[TBL] [Abstract][Full Text] [Related]
10. Management of protease inhibitor-associated hyperlipidemia.
Penzak SR; Chuck SK
Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
13. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
14. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
15. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Chan DC; Barrett HP; Watts GF
Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
[TBL] [Abstract][Full Text] [Related]
16. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
17. Comparative tolerability of the HMG-CoA reductase inhibitors.
Farmer JA; Torre-Amione G
Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
Spieker LE; Noll G; Hannak M; Lüscher TF
J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature.
Shammas NW; Kapalis MJ; Deckert J; Harris M; Dippel EJ; Labroo A; McKinney D
Prev Cardiol; 2003; 6(4):189-94. PubMed ID: 14605512
[TBL] [Abstract][Full Text] [Related]
20. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Nakamura N; Hamazaki T; Ohta M; Okuda K; Urakaze M; Sawazaki S; Yamazaki K; Satoh A; Temaru R; Ishikura Y; Takata M; Kishida M; Kobayashi M
Int J Clin Lab Res; 1999; 29(1):22-5. PubMed ID: 10356659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]